Drug intelligence / Profile preview

azuletil sodium

Development stage: Unknown
Lead developer: Kotobuki Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

AZULOXA is an oral small molecule medication developed by Kotobuki Pharmaceutical for the treatment of gastric ulcers and gastritis. Its active ingredient is azuletil sodium (KT1-32), an azulene derivative. The drug functions as a mucosal protective agent that promotes the healing of gastric lesions by stimulating blood vessel regeneration and accelerating the repair of the gastric mucosa. It has been approved and marketed in Japan and South Korea, and is available in both granule (2.5%) and tablet (15mg) formulations. AZULOXA is sometimes used in combination therapy with H2 receptor antagonists to enhance therapeutic outcomes in peptic ulcer management.

Brand names: AZULOXA
Other names: azuletileguareneeguarene sodium

Beyond the preview

Go deeper on azuletil sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azuletil sodium.

Explore the full profile